Difference between revisions of "Retifanlimab (Zynyz)"
Jump to navigation
Jump to search
(Created page with "==Mechanism of action== From [https://www.cancer.gov/publications/dictionaries/cancer-drug/def/retifanlimab NCI Drug Dictionary]: A proprietary humanized monoclonal antibody d...") |
m |
||
| (One intermediate revision by the same user not shown) | |||
| Line 6: | Line 6: | ||
==History of changes in FDA indication== | ==History of changes in FDA indication== | ||
| − | * | + | *2023-03-22: Granted accelerated approval for adult patients with metastatic or recurrent locally advanced [[Merkel cell carcinoma|Merkel cell carcinoma (MCC)]]. ''(Based on POD1UM-201)'' |
==Also known as== | ==Also known as== | ||
Latest revision as of 15:06, 25 December 2023
Mechanism of action
From NCI Drug Dictionary: A proprietary humanized monoclonal antibody directed against the negative immunoregulatory human cell surface receptor programmed cell death 1 (PD-1), with potential immune checkpoint inhibitory and antineoplastic activities. Upon administration, retifanlimab binds to and inhibits PD-1 and its downstream signaling pathways. This may restore immune function through the activation of T cells and cell-mediated immune responses against tumor cells.
Diseases for which it is used
History of changes in FDA indication
- 2023-03-22: Granted accelerated approval for adult patients with metastatic or recurrent locally advanced Merkel cell carcinoma (MCC). (Based on POD1UM-201)
Also known as
- Code name: INCMGA 0012, MGA 012
- Generic name: retifanlimab-dlwr
- Brand name: Zynyz